Kite Reports Promising Phase 1 Results for CAR T-Cell Therapies KITE-753 and KITE-363
Written by Emily J. Thompson, Senior Investment Analyst
Source: Businesswire
Updated: 1 hour ago0mins
- Clinical Trial Results: In a study involving 67 patients with relapsed/refractory large B-cell lymphoma, KITE-753 demonstrated a complete response rate of 79% among CAR-naïve patients at a median follow-up of 4 months, indicating its potential effectiveness in treatment.
- Safety Analysis: KITE-753 showed no dose-limiting toxicities at dose level 3, with 95% of patients experiencing serious adverse events primarily related to cytopenias, highlighting its favorable safety profile.
- Therapeutic Innovation: KITE-363 revealed that over 70% of complete responders maintained remission at 12 months during a median follow-up of 17.5 months, suggesting durable treatment effects that may provide hope for more patients.
- Market Outlook: Kite aims to expand the reach of its dual-targeting CAR T-cell therapies to a broader patient population, particularly those with advanced disease who have exhausted other treatment options, underscoring its strategic significance in the field of tumor immunotherapy.
GILD.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GILD is 133.83 USD with a low forecast of 105.00 USD and a high forecast of 150.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
17 Buy
3 Hold
0 Sell
Strong Buy
Current: 122.620
Low
105.00
Averages
133.83
High
150.00
Current: 122.620
Low
105.00
Averages
133.83
High
150.00
Truist
Gregory Renza
Buy
downgrade
$145 -> $140
2025-11-24
Reason
Truist
Gregory Renza
Price Target
$145 -> $140
2025-11-24
downgrade
Buy
Reason
Truist analyst Gregory Renza assumed coverage of Gilead with a Buy rating with a price target of $140, down from $145. The firm is positive on the continued strength for the company's HIV franchise, supported by Biktarvy's patent settlement and positive momentum across next-generation programs,most notably Yeztugo's PrEP launch and Bic/Len's positive phase 3 readout, pointing to a healthy outlook into the next-decade, the analyst tells investors in a research note. Truist adds that it also views the oncology franchise as a key growth pillar led by Trodelvy and anito-cel, further noting that Livdelzi's launch in PBC - Primary Biliary Cholangitis - is off to a strong start.
BMO Capital
BMO Capital
Outperform
maintain
$135
2025-11-24
Reason
BMO Capital
BMO Capital
Price Target
$135
2025-11-24
maintain
Outperform
Reason
BMO Capital says Phase 1 data from three patients in Kelonia Therapeutics' inMMyCAR study "look interesting," with all patients reaching MRD negativity by month one, but adds that the extremely small sample size and limited amount of patient follow-up "muddies comparisons" to Gilead (GILD) and Arcellx's (ACLX) anito-cel program. The tolerability profile of Kelonia's KLN-1010 "looks relatively clean," but the small sample size and the limited amount of patient follow-up "leave significant questions," adds the analyst, who keeps an Outperform rating and $135 price target on Gilead shares.
Mizuho
Outperform
maintain
$131 -> $140
2025-11-20
Reason
Mizuho
Price Target
$131 -> $140
2025-11-20
maintain
Outperform
Reason
Mizuho raised the firm's price target on Gilead to $140 from $131 and keeps an Outperform rating on the shares. The firm raised its price target primarily due to: Biktarvy's loss of exclusivity in the U.S. now expected to be 2036 instead of 2033 post generic lititgation settlements; the total addressable market for PrEP could be much larger than currently appreciated, and; the firm now models roughly 5% growth for Gilead's HIV business overall, from roughly 3% prior.
Scotiabank
NULL -> Outperform
initiated
$140
2025-11-12
Reason
Scotiabank
Price Target
$140
2025-11-12
initiated
NULL -> Outperform
Reason
Scotiabank initiated coverage of Gilead with an Outperform rating and $140 price target.
See All Ratings
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What factors contribute to significant ETF withdrawals like those involving GILD?
How does monitoring ETF flows impact underlying holdings like GILD?
Will Kymera's KT-621 phase IIb trial results meet investor expectations by 2027?
Can Gilead Sciences maintain its growth trajectory in the HIV treatment market?